Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Tvardi Therapeutics to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.
Volatility and Risk
Tvardi Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics’ peers have a beta of -3.77, meaning that their average stock price is 477% less volatile than the S&P 500.
Earnings & Valuation
This table compares Tvardi Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Tvardi Therapeutics | $7.14 million | -$18.21 million | -0.48 |
| Tvardi Therapeutics Competitors | $3.54 billion | $3.16 billion | 552.54 |
Tvardi Therapeutics’ peers have higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Tvardi Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
| Tvardi Therapeutics Competitors | -2,381.34% | -218.59% | -15.77% |
Insider and Institutional Ownership
44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Tvardi Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
| Tvardi Therapeutics Competitors | 7803 | 13892 | 25795 | 1039 | 2.41 |
Tvardi Therapeutics presently has a consensus price target of $9.40, suggesting a potential upside of 608.90%. As a group, “Pharmaceuticals” companies have a potential upside of 24.23%. Given Tvardi Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than its peers.
Summary
Tvardi Therapeutics beats its peers on 8 of the 13 factors compared.
About Tvardi Therapeutics
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
